Clinical Trial Update: A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder [Phase 3]

View source ↗

Summary

A Phase 3 safety and effectiveness study of methylphenidate HCl extended-release tablets in adults with attention-deficit/hyperactivity disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• methylphenidate HCl extended-release tablets (methylphenidate hydrochloride extended-release)

Snippet

Sponsor: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 3 | Status: COMPLETED